


2021 American Diabetes Association
 Glucose Lowering Medications in Type 2 Diabetes
 Diabetes Care 2021 Jan;44 (Supplement 1): S111-124
 (Used with permission from Diabetes Care, August 2021)



GLP-1 Receptor Agonists

Product	Dosing	FDA Indications
Exenatide (Byetta®)	5-10mg twice daily	Adjunct in T2DM
Exenatide ER (Bydureon®)	2mg once weekly	Adjunct in T2DM
Dulaglutide (Trulicity®)	0.75-4.5mg once weekly	Adjunct in T2DM, risk reduction of CV events with DM & <i>CVD or multiple risk factors</i>
Liraglutide (Victoza®)	0.6 x 1 week, 1.2-1.8mg daily	Adjunct in T2DM, risk reduction of CV events with DM & CVD
Lixisenatide (Adlyxin®)	10mg x 2 week, 20mg daily	Adjunct in T2DM
Semaglutide (Ozempic®)	0.25 once weekly x 1 month, 0.5-1mg weekly	Adjunct in T2DM, risk reduction of CV events with DM & CVD
Semaglutide (Rybelsus®)	3mg daily x 1 month, 7-14mg daily (ORAL)	Adjunct in T2DM

Adverse Effects:

- Nausea, vomiting, diarrhea-minimize fatty/greasy foods, plan smaller meals
- black box warning against use in patients with family history of medullary thyroid cancer or multiple endocrine neoplasia-2

SGLT-2 Inhibitors

Product	Dosing	eGFR Dose Adjustment	FDA Indications
Canagliflozin (Invokana®)	100mg daily 300mg daily	eGFR 45-60 ml/min: 100mg/d eGFR <45 ml/min + >300 mg/d urine albumin: 100mg/d eGFR <45 ml/min + <300 mg/d urine albumin: do not use	<ul style="list-style-type: none"> • Adjunct in T2DM • Risk reduction of major cardiovascular events in T2DM and established CV disease • Risk reduction of ESRD, doubling of SCr, CV death, and hospitalization for HF in T2DM & diabetic nephropathy
Dapagliflozin (Farxiga®)	5mg daily 10mg daily	Discontinue if eGFR <45 ml/min	<ul style="list-style-type: none"> • Adjunct in T2DM • Risk reduction of HF hospitalization with T2DM and CV disease or multiple risk factors • Reduce risk of CV death and hospitalization for HF in HFREF
Empagliflozin (Jardiance®)	10mg daily 25mg daily	Discontinue if eGFR <30 ml/min	<ul style="list-style-type: none"> • Adjunct in T2DM • Risk reduction of CV mortality with DM & established CV disease
Ertugliflozin (Steglatro®)	5mg daily 15mg daily	Discontinue if eGFR <60 ml/min	<ul style="list-style-type: none"> • Adjunct in T2DM

Adverse Effects:

Genital mycotic infections, urinary tract infections, hypotension, volume depletion Encourage appropriate hygiene and hydration)